Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Verheijen

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Trends in Genetics : TIG|March 26, 2018
Understanding Alzheimer Disease at the Interface between Genetics and TranscriptomicsJan Verheijen, Kristel Sleegers
Thrombosis and Haemostasis|September 30, 2003
Genetic deletion of tissue-type plasminogen activator (t-PA) in APOE3-Leiden mice reduces progression of cholesterol-induced atherosclerosisFarhad Rezaee, Marion Gijbels, Erik Offerman, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 20, 2019
Therapeutic approaches in Congenital Disorders of Glycosylation (CDG) involving N-linked glycosylation: an updateJan Verheijen, Shawn Tahata, Tamas Kozicz, et al.
Acta Oncologica (Stockholm, Sweden)|September 17, 2010
Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survivalBirgitte V Offersen, Marianne M Knap, Michael R Horsman, et al.
Disease Models & Mechanisms|October 23, 2019
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDGSangeetha Iyer, Feba S Sam, Nina DiPrimio, et al.
Journal of Inherited Metabolic Disease|May 12, 2019
A novel phosphoglucomutase-deficient mouse model reveals aberrant glycosylation and early embryonic lethalityBijina Balakrishnan, Jan Verheijen, Arielle Lupo, et al.
Stroke|December 13, 2005
Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation formsJoost P G Sluijter, Wilco P C Pulskens, Arjan H Schoneveld, et al.
Mayo Clinic Proceedings|October 10, 2024
Prevalence, Penetrance, and Phenotypic Manifestation of Cardiomyopathy-Associated Genetic Variants in the General Population: Insights from a Mayo Clinic Biobank StudyMarta Figueiral, Alessia Paldino, Matheus Vernet Machado Bressan Wilke, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 19, 2015
A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42Kristel Sleegers, Karolien Bettens, Arne De Roeck, et al.
Cells|February 12, 2026
<i>PICALM</i> Genetic Variant Alters mRNA Expression Without Affecting Protein Levels or Tau Spreading in Alzheimer's DiseaseKunie Ando, Lidia Lopez-Gutierrez, Salwa Mansour, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Trends in Genetics : TIG|March 26, 2018
Understanding Alzheimer Disease at the Interface between Genetics and TranscriptomicsJan Verheijen, Kristel Sleegers
Thrombosis and Haemostasis|September 30, 2003
Genetic deletion of tissue-type plasminogen activator (t-PA) in APOE3-Leiden mice reduces progression of cholesterol-induced atherosclerosisFarhad Rezaee, Marion Gijbels, Erik Offerman, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 20, 2019
Therapeutic approaches in Congenital Disorders of Glycosylation (CDG) involving N-linked glycosylation: an updateJan Verheijen, Shawn Tahata, Tamas Kozicz, et al.
Acta Oncologica (Stockholm, Sweden)|September 17, 2010
Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survivalBirgitte V Offersen, Marianne M Knap, Michael R Horsman, et al.
Disease Models & Mechanisms|October 23, 2019
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDGSangeetha Iyer, Feba S Sam, Nina DiPrimio, et al.
Journal of Inherited Metabolic Disease|May 12, 2019
A novel phosphoglucomutase-deficient mouse model reveals aberrant glycosylation and early embryonic lethalityBijina Balakrishnan, Jan Verheijen, Arielle Lupo, et al.
Stroke|December 13, 2005
Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation formsJoost P G Sluijter, Wilco P C Pulskens, Arjan H Schoneveld, et al.
Mayo Clinic Proceedings|October 10, 2024
Prevalence, Penetrance, and Phenotypic Manifestation of Cardiomyopathy-Associated Genetic Variants in the General Population: Insights from a Mayo Clinic Biobank StudyMarta Figueiral, Alessia Paldino, Matheus Vernet Machado Bressan Wilke, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 19, 2015
A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42Kristel Sleegers, Karolien Bettens, Arne De Roeck, et al.
Cells|February 12, 2026
<i>PICALM</i> Genetic Variant Alters mRNA Expression Without Affecting Protein Levels or Tau Spreading in Alzheimer's DiseaseKunie Ando, Lidia Lopez-Gutierrez, Salwa Mansour, et al.
Pageof 2